Literature DB >> 22718190

Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation.

Thien Anh Ho1, Nathalie Godefroid, Damien Gruzon, Jean-Philippe Haymann, Céline Maréchal, Xueqi Wang, Andreas Serra, Yves Pirson, Olivier Devuyst.   

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is associated with a urine-concentrating defect attributed to renal cystic changes. As PKD genes are expressed in the brain, altered central release of arginine vasopressin could also play a role. In order to help determine this we measured central and nephrogenic components of osmoregulation in 10 adults and 10 children with ADPKD, all with normal renal function, and compared them to 20 age- and gender-matched controls. Overnight water deprivation caused a lower rise in urine osmolality in the patients with ADPKD than controls, reflecting an impaired release of vasopressin and a peripheral defect in the patients. The reactivity of plasma vasopressin to water deprivation, as found in controls, was blunted in the patients with the latter showing lower urine osmolality for the same range of plasma vasopressin. The maximal urine osmolality correlated negatively with total kidney volume. Defective osmoregulation was confirmed in the children with ADPKD but was unrelated to number of renal cysts or kidney size. Thus, patients with ADPKD have an early defect in osmoregulation, with a blunted release of arginine vasopressin. This reflects expression of polycystins in hypothalamic nuclei that synthesize vasopressin, and this should be considered when evaluating treatments targeting the vasopressin pathway in ADPKD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22718190     DOI: 10.1038/ki.2012.225

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  22 in total

1.  Hyperglycemia in the absence of cilia accelerates cystogenesis and induces renal damage.

Authors:  Kelli M Sas; Hong Yin; Wayne R Fitzgibbon; Catalin F Baicu; Michael R Zile; Stacy L Steele; May Amria; Takamitsu Saigusa; Jason Funk; Marlene A Bunni; Gene P Siegal; Brian J Siroky; John J Bissler; P Darwin Bell
Journal:  Am J Physiol Renal Physiol       Date:  2015-04-22

2.  Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.

Authors:  Olivier Devuyst; Arlene B Chapman; Ron T Gansevoort; Eiji Higashihara; Ronald D Perrone; Vicente E Torres; Jaime D Blais; Wen Zhou; John Ouyang; Frank S Czerwiec
Journal:  J Am Soc Nephrol       Date:  2016-12-05       Impact factor: 10.121

3.  Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.

Authors:  Ron T Gansevoort; Maatje D A van Gastel; Arlene B Chapman; Jaime D Blais; Frank S Czerwiec; Eiji Higashihara; Jennifer Lee; John Ouyang; Ronald D Perrone; Katrin Stade; Vicente E Torres; Olivier Devuyst
Journal:  Kidney Int       Date:  2019-03-09       Impact factor: 10.612

4.  Polycystic kidney disease: An early urea-selective urine-concentrating defect in ADPKD.

Authors:  Lise Bankir; Daniel G Bichet
Journal:  Nat Rev Nephrol       Date:  2012-06-26       Impact factor: 28.314

5.  Copeptin is associated with kidney length, renal function, and prevalence of simple cysts in a population-based study.

Authors:  Belen Ponte; Menno Pruijm; Daniel Ackermann; Philippe Vuistiner; Idris Guessous; Georg Ehret; Heba Alwan; Sonia Youhanna; Fred Paccaud; Markus Mohaupt; Antoinette Péchère-Bertschi; Bruno Vogt; Michel Burnier; Pierre-Yves Martin; Olivier Devuyst; Murielle Bochud
Journal:  J Am Soc Nephrol       Date:  2014-09-30       Impact factor: 10.121

Review 6.  Polycystic kidney disease.

Authors:  Carsten Bergmann; Lisa M Guay-Woodford; Peter C Harris; Shigeo Horie; Dorien J M Peters; Vicente E Torres
Journal:  Nat Rev Dis Primers       Date:  2018-12-06       Impact factor: 52.329

Review 7.  Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?

Authors:  Peter Janssens; Caroline Weydert; Stephanie De Rechter; Karl Martin Wissing; Max Christoph Liebau; Djalila Mekahli
Journal:  Pediatr Nephrol       Date:  2017-04-28       Impact factor: 3.714

Review 8.  Vasopressin-2 receptor signaling and autosomal dominant polycystic kidney disease: from bench to bedside and back again.

Authors:  Markus M Rinschen; Bernhard Schermer; Thomas Benzing
Journal:  J Am Soc Nephrol       Date:  2014-02-20       Impact factor: 10.121

Review 9.  Renal transplantation in autosomal dominant polycystic kidney disease.

Authors:  Nada Kanaan; Olivier Devuyst; Yves Pirson
Journal:  Nat Rev Nephrol       Date:  2014-06-17       Impact factor: 28.314

Review 10.  Novel insights into TRPV4 function in the kidney.

Authors:  Oleh Pochynyuk; Oleg Zaika; Roger G O'Neil; Mykola Mamenko
Journal:  Pflugers Arch       Date:  2012-12-04       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.